LEADER 04186nam 2200937z- 450 001 9910576885303321 005 20220621 035 $a(CKB)5720000000008321 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/84441 035 $a(oapen)doab84441 035 $a(EXLCZ)995720000000008321 100 $a20202206d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aCoronaviruses Research in BRICS Countries 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (168 p.) 311 08$a3-0365-4028-8 311 08$a3-0365-4027-X 330 $aSARS-CoV-2 has infected more than 105 million people worldwide. During this pandemic, researchers and clinicians have been working to understand the molecular mechanisms that underpin viral pathogenesis by studying viral-host interactions. Now, with the global rollout of various COVID-19 vaccines-based on the neutralization of the spike protein using different technologies-viral immunology and cell-based immunity are being investigated. Researchers are also studying how various SARS-CoV-2 genetic mutations will impact the efficacy of these COVID-19 vaccines. At the same time, various antiviral drugs have been identified or repurposed that have potential as anti-SARS-CoV-2 treatments. BRICS (Brazil, Russia, India, China, and South Africa) is the acronym used to associate five major emerging national economies. The BRICS countries are known for their significant influence on regional affairs, including being leaders in scientific and clinical research and innovation. This Special Issue includes researchers from BRICS countries, in particular South Africa, involved in the study of SARS-CoV-2 and COVID-19. Original articles, as well as new perspectives or reviews on the matter, were welcomed. Research in the fields of vaccine studies, pathogenesis, genetic mutations, viral immunology, and antiviral drugs were especially encouraged. 606 $aEpidemiology and Medical statistics$2bicssc 606 $aMedicine and Nursing$2bicssc 610 $aaerosol 610 $abioinformatics and vaccine development 610 $aBrazil 610 $abreakthrough 610 $aconvalescent plasma 610 $acoronavirus disease 2019 (COVID-19) 610 $acorticosteroids 610 $aCOVID-19 610 $aCOVID-19 and nanotechnology 610 $aCOVID-19 testing 610 $aDelta and Delta plus variant 610 $adental aerosol-generating procedures 610 $adetection 610 $adiabetes 610 $adifferent settings 610 $aE484K 610 $aepitope coverage 610 $aextra-oral suction 610 $agenomic epidemiology 610 $ahigh-volume evacuation 610 $ahospital mortality 610 $ahumoral response 610 $aimmunoassay 610 $aIndia 610 $aintervention strategies 610 $aintubation 610 $alow-volume saliva ejector 610 $amodels 610 $ananomedicine in South Africa 610 $ananotechnology 610 $aneutralizing antibody (NAb) 610 $aNSW 610 $aprotein microarray 610 $aquantitative antibody binding 610 $areverse zoonosis 610 $aSARS-CoV-2 610 $aSARS-CoV-2 antibodies 610 $aSARS-CoV-2 nucleocapsid protein 610 $asevere acute respiratory syndrome coronavirus (SARS-CoV-2) 610 $asplatter 610 $atreatment 610 $avaccine 610 $avaccine development in South Africa 610 $avariant of Interest 610 $aVRDL 610 $awildlife 615 7$aEpidemiology and Medical statistics 615 7$aMedicine and Nursing 700 $aFielding$b Burtram C$4edt$01291013 702 $aSchäfer$b Georgia$4edt 702 $aFielding$b Burtram C$4oth 702 $aSchäfer$b Georgia$4oth 906 $aBOOK 912 $a9910576885303321 996 $aCoronaviruses Research in BRICS Countries$93021755 997 $aUNINA